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ABSTRACT
Chlamydia Trachomatis and Neisseria Gonorrhoeae rank as the two most commonly reported
sexually transmitted diseases (STDs) in the United States. Under limited budget, publicly
funded clinics are not able to screen and treat the two diseases for all patients. They have to
make a decision as to which group of population shall go through the procedure for screening
and treating the two diseases. Therefore, we propose a cubic integer programming model
on maximizing the number of cured diseases. At the same time, a two-step algorithm is
established to solve the cubic integer program. We further develop a web-server, which
immediately make recommendation on identifying population groups, screening assays and
treatment regimens. Running on the empirical data provided by the Centers for Disease
Control and Prevention, our program gives more accurate optimal results comparing to MS
Excel solver within a very short time.
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CHAPTER 1
INTRODUCTION
Chlamydia trachomatis(CT) and Neisseria gonorrhoeae(GC) are the two most commonly
reported sexually transmitted diseases (STDs) in the United States. In 2005, there were
976,445 chlamydia infections reported to the Centers for Disease Control and Prevention
(CDC) from 50 states and the District of Columbia. This case count corresponds to a rate
of 332.5 cases per 100,000 population, an increase of 5.1% compared with the rate of 316.5
in 2004. In 2005, there were 339,593 cases of gonorrhea reported in the United States with
the rate of 115.6 cases per 100,000 population, the first increase in gonorrhea since 1999 as
reported in [10].
Many cases of CT and GT diseases are screened and treated by publicity funded clinics.
In reality, these clinics may not have sufficient budgets to screen all eligible women with the
most effective CT/GC tests and to offer these infected ones with more expensive, single-
dose treatment that optimizes compliance. To effectively use limited resources, CT and GC
control programs usually provide selective screening based on some defined guidelines. CDC
recommends annual screening for CT and GC for sexually active adolescents and young
women [7]. The U.S. Preventive Services Task Force (USPSTF) recommends screening all
sexually active women, including those who are pregnant, for gonorrhea infection if they are
at increased risk for infection [8].
For CT and GC control programs, however, identifying which subpopulations to screen
for chlamydial and/or gonorrheal infections is just one part of a complicated problem. The
availability of several testing assays with various performances and costs presents a challenge
for screening strategies: Newer diagnostic tests that are less intrusive and more sensitive
2offer increased opportunities for screening, but at a greater cost. So another question is
whether it is better to use a more sensitive and expensive test to screen fewer patients, or
to use a relatively cheaper and less sensitive test to screen a greater number of patients. To
further complicate the situation, test manufacturers market combination tests or bundled
test at prices that are more lucrative than the price of a single-pathogen test. This situation
encourages the testing for GC even when its prevalence in the population is extremely low.
We establish a model to provide an optimal strategy recommendation for screening and
treating CT and/or GC with limited budget. Our model maximizes the number of possi-
ble cured cases for these diseases. We divide the problems into a few cases and reduce
the problem to the classical knapsack problem. Moreover, we construct a web-application
embedded with our designed algorithm to provide optimal strategy for publicity funded pro-
grams. We used JSP, Tomcat and MySql as our web-programming tools. The corresponding
web-application has been established for two groups of users: those who can change the all
parameters (as super users) and those who only input data on populations and budget (as
anonymous users). With our recommended strategy, clinical managers can identify at risk
groups from within the patient population and select certain screening assays and treat-
ments for them. Furthermore, we find that our algorithm is more accurate comparing to
Excel Solver and easy to implement.
CHAPTER 2
GENERAL SETTING AND MATHEMATICAL MODEL
The object is set to maximize the number of cured disease cases under a fixed budget. One
patient with both two diseases cured is counted as two cases. We believe this goal is more
reasonable than simply maximize the number of cured patients. The general mathematical
model for a clinic is described below and the exact model based upon the empirical data
from CDC will be given in Section 3 with tedious details. Let b denote the total annual
funding available to a clinic for screening and treatment for CT and GC.
1. Population assumption. Assume the patient population is divided into m groups.
Let xi be the binary indicator such that xi = 1 if the group i is identified and xi = 0
otherwise.
2. Screening assumption. Assume there are s available screening assays. Let yj be the
binary indicator such that yj = 1 if the screening assay j is used and yj = 0 otherwise.
3. Treatment assumption. Assume there are t available treatment assays. Let zk be
the binary indicator such that zk = 1 if the assay k is used and zk = 0 otherwise. Since
we may choose one assay for CT and one for GC simultaneously, we will present this
set of variables slightly differently in the realistic model later.
4. Target function and constraints. Let Rijk denote the number of cases of diseases
been cured, Cijk denote the cost if group i is identified and screening j and treatment
k are used. If a patient has both disease cured, the disease cases will be counted twice.
Then the problem can be expressed below:
Max
∑
i,j,k
Rijk · xiyjzk :=
m∑
i=1
s∑
j=1
t∑
k=1
Rijk · xiyjzk. (2.1)
4subject to ∑
i,j,k
Cijk · xiyjzk ≤ b (2.2)
where A := B means naming B as A.
5. Additional constraints. CDC requires, for each disease, the same screening assay
and the same treatment must be applied for all patients treated at the clinic, i.e.
no favor is given to particular patient(s) or group(s). Consequently, the following
constraints are applied:
s∑
j=1
yj = 1 and (2.3)
t∑
k=1
zk = 1. (2.4)
This model is a binary cubic programming problem. The only known algorithms for
solving this model are based on exhausting cases, which runs on exponential time [17].
Although some softwares such as MPL (Mathematical Programming Language), Lingo, Excel
Solver were embedded with different algorithms to solve nonlinear integer programming, they
only provide approximation solutions when the size of the problem is big. We will create an
algorithm that can provide an exact solution rather than approximation solutions.
Because (2.3) and (2.4) that there is only one possible j such that yj = 1 and there is
only one possible k such that zk = 1, We can transfer the model into s · t sub-models and
each sub-model is a knapsack problem. The knapsack problem in general is a NP-complete
problem [16]. We use the well-know branch-and-bound algorithm of Horowitz-Sahni to solve
it. We will compare and discuss our algorithm with Excel Solver’s algorithm in the algorithm
section later.
5There are three treatments choices: treating CT alone, treating GC alone, or treating
both CT and GC. We find it is more convenient to use double index variable z(k,l) instead
of single index variable zk. Suppose we have t treatment assays in total. Let z(k,l), where
k = 0, 1, ..., q and l = 0, 1, ..., (t− q), be the binary indicator such that z(k,l) = 1 if the assay
k is used for treating CT and assay l is used for treating GC. z(k,l) = 0 means either the
kth CT treatment or the jth GC treatment is selected. z(0,0) means none of the assays are
selected and it is always equal to 0. In another word, we will always treat the patients so
z(0,0) = 1 never happens. z(0,l) = 1 denotes only GC treatment assay l is selected, z(k,0) = 1
denotes only CT treatment assay k is selected. So the number of combinations of screening
and treatment is not simply s · t although we know it is bounded above by s · q · (t− q).
For each choice of screening assay and treatment, if we assume that the infection rate
of each population group is given, the costs and cured patients can be calculated. Under
the given screening assay and treatment, the question now is to choose population groups to
maximize the number of cured cases with the total costs under a fixed budget, is a typical
knapsack problem.
We now give an example for the model to further demonstrate how our model works.
Suppose that a clinic has 10,000 patients who can be divided into 12 sub-population groups
by ages and races, 2 single CT screening assays, 2 single GC screening assays, 3 combo
screening assays; 2 CT single treatment assays, and 2 GC single treatment assays available.
According to those assumptions, there are 52 combinations of screening and treatments as
described below.
1. Single screening test and single treatment targeting on CT.
A CT screening test is given to everyone in the sub-population and then a CT treatment
is given to those who are tested positively. Given two CT screening assays and two
6CT treatments available, there are a total of our combinations using a single screening
test and a single treatment for CT.
2. Single screening test and single treatment targeting on GC.
With the same logic as the previous scenario, we also have four combinations to screen
and treat GC.
3. Sequence screening tests that tested for CT first.
A CT screening test is performed and then an additional GC test is performed to those
who tested positively on CT; and a CT treatment is given for those who test positively
on CT and a GC treatment is given for those tested positively on GC. This provides
16 combinations (two test assays for CT, two test assays for GC, two treatments for
CT and two treatments for GC).
4. Sequence screening tests that tested for GC primarily.
Same as the previous case, there are 16 combinations of screening and treatment in
this case.
5. Combo screening test for both CT and GC.
In this scenario, a combo test is applied to test both CT and GC at the same time to
a sub-population. CT or GC are treated if patients have positive test results for CT
or GC. Since there are three combo test assays, two test assays for CT and two test
assays for GC, there are 3 · 2 · 2 combinations.
CHAPTER 3
THE BOUNDS OF BUDGETS
3.1 The Bounds of Budgets.
Insufficient budget occurs in the situation where the budget is not enough for identifying any
single group for a screening test and a treatment. The minimum budget is the least amount
of budget such that there is a way to identify one group to get screened and treated. On the
other hand, the maximum budget is the least amount budget to identify all population, given
the most expensive screen and treatment. We will determine the maximum and minimum
budget as following.
The Maximum Budget.
The maximum budget can be obtained if all population are screened for both CT & GC and
those with positive tests are treated. Assuming that xi = 1 for all i in calculating cost in
Section 3.2., we obtain the maximum budget as below.
MaxB := max
j,k,l
{
m∑
i=1
Popi · Costijkl}, (3.1)
where i, j, k, and l (i = 1, ...,m; j = 1, ..., s; k = 1, ..., t; and l = 1, ..., r) run over each possi-
ble screening and each corresponding treatment and we assume that the population is divided
into m groups. The number of cases is bounded by s · t · r. Furthermore, maxj,k,l{Costijkl}
is the cost for screening and treating one patient in the ith group with the most expensive
assay and medication.
8The Minimum Budget. The minimum budget is denoted by m when only one group of
population is screened and treated. We use the following formula to compute it.
MinB := min
i,j,k,l
{Popi · Costijkl}, (3.2)
where i, j, k, and l run over each possible group and each possible screening test and each
corresponding treatment. The number of cases is bounded by m · s · t · r.
Reasonable Budget Range.
Any budget between MaxB and MinB is called the reasonable budget and the interval
[MinB,MaxB] is called the reasonable budget range.
CHAPTER 4
SOLVING THE MODEL
The cubic binary programming belongs to nonlinear optimization category. We can use Excel
Solver’s approximation algorithm to solve the problem. However, we do not know how good
those results are. By converting the model to a knapsack problem, we proposed a two-step
exact algorithm to solve the problem. With the empirical data from CDC, we compare our
solutions generated by our algorithm to the solutions obtained by using Excel Solver.
4.1 Two-step Algorithm
Based on the data in appendix, we used the constrains
∑
j yj = 1 and
∑
(k,l) z(k,l) = 1 to
convert the model in section 2 into 52 knapsack problems. Here, as our first step, we wrote an
exhausting algorithm to analyze the number of knapsacks. At each knapsack problem, there
are 12 population as the number of items. In addition, we consider the costs Costijkl and
cured cases Curijkl as “weights” and “prices”, and the budget becomes the “capacity”. Then
we use the classical Horowitz-Sahni branch-and-bound algorithm [14] to find the optimal
result for each knapsack problem. At the second step, we find the best strategy within these
52 local optimal results. This strategy will be our global optimal result. One may refer our
flowchart in Figure 4.1.
4.2 Excel Solver for Knapsack Problems
Microsoft Excel Solver[2] uses the Generalized Reduced Gradient (GRG2) Algorithm for
optimizing nonlinear problems. This algorithm was developed by Leon Lasdon, of the Uni-
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Figure 4.1: The flowchart of the two-step algorithm
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versity of Texas at Austin, and Allan Waren, of Cleveland State University. Linear and
integer problems use the simplex method with bounds on the variables and the branch and
bound method, implemented by John Watson and Dan Fylstra, of Frontline Systems, Inc[2].
Solver can solve our model.
CHAPTER 5
ALGORITHMS DISCUSSION
We implement the model with JAVA and Excel VBA separately. As for the proposed al-
gorithm, the calculation running time mainly depends on the second step calculation after
converting the original problem into many knapsack problems. The proposed algorithm is an
exact algorithm while using the classic branch-and-bound algorithm as its the second step.
We also tried the dynamic programming [14] as for the second step before. However, the
calculation space greatly depends on budget with dynamic programming. Greater budget
demands a bigger space. Therefore, we abandon the dynamic programming and adopted
branch-and-bound for our web-application. We further compared our algorithm to Excel
Solver and find that our algorithm is more accurate than Solver’s nonlinear algorithm. As
for Excel Solver, we use embedded standard Solver in Excel 2003. The following results were
run on an Intel Celeron M 1.6GHz processor and a RAM of 512MB.
5.1 Two-step Algorithm v.s. Solver’s GRG2 Algorithm
Excel Solver can solve the proposed nonlinear model with GRG2 algorithm. However, Excel
Solver is not open source. It has been criticized for its calculation capacity and accuracy.
“Solver is NOT a very robust tool and may fail to find solutions! In general, finding roots
to nonlinear functions is a very difficult problem. Excel does a poor job compared to more
powerful programs such as Matlab.”[4]. Solver is using the approximation algorithm which
is not as accurate as exact algorithm and it might fail to find a solution or it might time out
before reaching a solution[9].
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We find that our web-solver with our proposed algorithm has a faster running time
and provides more accurate than the Excel Solver. For example, as for budget of $50,000,
110 cured disease in term of cases are achieved under the optimal strategy selected by
our algorithm. Our strategy suggests to treat CT and GC together. On contrary, only 101
disease cases were cured with a strategy of single CT treatment by Solver’s GRG2 algorithm.
Furthermore, under a budget of $70,000, both of two-step algorithm and GRG2 algorithm
suggest to treat CT and GC together. However, Solver’s result identifies less patient groups
than ours. Therefore, Solver’s strategy generates 144 cured cases which is less than two-
step algorithm’s 147 cases. We have examined the optimal strategy selected by the two
algorithms under budget of $10,000, $50,000, $70,000, $100,000 and $500,000 in Table 5.1.
We notice that our algorithm could generate a better solution than Solver’s. If we adopte
branch-and-bound as our second step, we could always see that our proposed algorithm has
a faster running time on the same machine. As for $500,000, the budget is about to exceed
the maximum optimal budget, and the cured cases depend on the assays parameters instead
of the budget by a large amount. The two algorithms generate same results.
5.2 Second Step with Excel Solver, Dynamic Program and Branch-and-Bound
in Java
The two-step algorithm results given in appendix differ from each other by the second step
algorithm. We implement Excel Solver, the dynamic algorithm and branch-and-bound algo-
rithm separately as our second step to calculate the knapsack. We use Excel Solver’s linear
algorithm and VBA. It produces the optimal results from time to time. However, solving
simple knapsack problems and doing loops in VBA demand running time. As one may see
that from Table 5.1, Solver’s linear programming as our second step is a kind of slow in term
14
of running seconds.
Both dynamic and branch-and-bound algorithms produce the optimal solutions. How-
ever, dynamic programming consumes a huge amount of the computer memory. The dy-
namic programming algorithm heavily depends on the budget. The nature of O(nC) time
and O(nC) space make the calculations difficult when computing large budget over $200,000
for our data. One may see from the Table 5.1 that the running seconds of the dynamic
programming as the second step is increasing dramatically. The computer can not handle
the calculation while the budget is $500,000. Among the three different approaches, Java
Branch-and-bound provided the fastest calculation.
15
Table 5.1: Algorithm results
Two-step Algorithm Solver’s GRG2
Solver’s Linear Java Dynamic Java BnB
n = 10000
Cured cases 12 12 12 12
Costs 7116.67 7116.67 7116.67 7116.67
Running time 17 1 <1 3
Strategy
Screening BD ProbeTec CT same same same
Treatment DXC same same same
n = 50000
Cured cases 110 110 110 101
Costs 47132.36 47132.36 47132.36 41758.62
Running time 14 9 <1 4
Strategy
Screening Pace 2 CT same same same
Treatment DXC+CFX same same DXC
n = 70000
Cured cases 147 147 147 144
Costs 69632.28 69632.28 69632.28 64679.69
Running time 14 11 <1 4
Strategy
Screening Pace 2 CT same same same
Treatment DXC+CFX same same same
n = 100000
Cured cases 198 198 198 197
Costs 97387.32 97387.32 97387.32 96693.52
Running time 14 44 <1 1
Strategy
Screening BD ProbeTec CT same same same
Treatment DXC+CFX same same same
n = 500000
Cured cases 381 out of memory 381 381
Costs 464877.85 n/a 464877.85 464877.85
Running time 14 n/a <1 1
Strategy
Screening BD ProbeTec CT n/a same same
Treatment DXC+CFX n/a same same
DXC=Doxycycline and CFX=Ceftriaxone
CHAPTER 6
NUMERICAL RESULTS ANALYSIS
Here we give the calculation results based on the given data on table 7.1, 7.2 and 7.3. We
also assume that 45% patients infected with GC have CT disease at the same time. We keep
all other parameters unchanged and increase budgets per capita by one cent. We record
the budget while the cured diseases increases by one case. Thus, the Figure 6.1 shows the
relation between the two variables. Solid line in figure represents the total case number of
cured diseases regarding CT and GC. The dotted line in figure represents the cured disease
number regarding CT. The vertical distance of the two curves is the cured case number
regarding GC.
solid line: total cured disease cases.
dotted line: cured CT disease cases.
Figure 6.1: The cure of budget per captica V.S. cured disease case is concave
We could expect to see that the graph is a discrete concave curve. This also implies
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that as the budget per capita increases within the reasonable budget region, the total cured
disease cases increase for each optimal strategy selected by our model. Why does it look like
this? Because both of the money and the number of of cured cases are discrete. We don’t
have money unit below one penny and case number less than one in reality. Therefore, after
increasing budget by one penny, we can see the number of cured cases either increase to
another integer or keep unchanged. As for the concave, the increment of cured case number
over low unit budget are significantly larger than those over high unit budget. It makes sense
in reality: while a clinic increases budget from nothing to $10, the cured case number will
be increase to around 200 cases. However, if the clinic increases budget from $70 to $80,
the cured case number will be increased by less than 50 cases. This situation demonstrates
that the budget does not always play an important role in our model. While the budget is
sufficient large, the cured case number does not depend on the budget but the medication
effectiveness. That’s also the reason while the budget is over $80, the number of cured cases
will always keeps to certain level on the graph. Furthermore, the corresponding cost-saving
value does not increase as budget per capita increases. This can be shown from the Figure
6.2.
This graph tells us that the positive cost-saving value reaches its highest point while the
budget is around $7. In another word, we could save around $50,000 with the earlier testing
and treatment strategy under a budget around $7. Beyond the budget, we can see that
the cost-saving value decreases to $0 at a budget level around $17. Over the budget level
of $17, the cost-saving value is a negative number because the expenditure on testing and
treatment exceed the monetary value of averted sequelae of CT and GC infections. While
budget is over $80, the cost-saving value will stick to certain level on the graph. This graph
is just one of economical factor over the budget to illustrate the relation between the two
variable. It does not recommend that we have to stick our budget below $17 because we
18
Figure 6.2: The curve of budget per captica V.S. cured disease case shows that the cost-saving
value increases at first and then decreases as budget keeps increasing.
can not measure the prevention effect with just one economic factor. On the other hand, as
the budget increases to a large amount saying over $20, we do see that cured cases increase
while the cost-saving decreases already to negative.
6.1 Economical Efficiency v.s. Human Health
If we want to focus on the cost-saving value and want to spend each penny efficiently, that’s
another story with absolutely different graphs. In that case, the target function will be
changed and the optimal strategy will be selected according to maximize an economical
factor. At the same time, a moral question is raised: should our health system target on
treating more people at a not perfectly efficient operations, or should our system concern
more economic efficiency by leaving some patients who probably have diseases untreated?
As more and more researchers criticize the US health system is inefficient, we have to con-
sider the circumstance that there exists a win-lose situation like the problem we exposure
19
here. Here, we suggest in future study the money measure for individual health should be
introduced while researchers use money as a mean to measure the health system efficiency.
In another word, health should be mathematically measurable so that we can develop an-
other quantitative model for making an efficient health system decision without hurting any
individual health.
6.2 Combo Test v.s. Single Test
Testing procedure plays an important role in selecting to treat one disease or two diseases.
If we have combo test assays at the beginning, then we are more likely to treat two diseases
together. If we only test one disease at first, then we are going to treat just one disease.
However, if we use two single tests that is to test one disease at first and test another later,
then we are going to treat two diseases together. Therefore, we find that test assays’ type
determine if we are going to treat one disease or two diseases.
If we fixed the medications’ parameters and other costs, then we can see that the prices
of medications have a great effect on the optimal strategies. If the price of single test assays
are close to combo tests, then the optimal strategy selected by our model is more favorable
to the combo essay test and treat CT and GC together. However, if the prices of combo tests
are double to single test assays, then the model does not give more favorite to combo tests
based on the data in the tables in section 3. This makes sense in reality. Intuitively speaking,
once you can use combo test to treat CT and GC together, you won’t use single test with
similar price to treat just one disease. Treating two diseases increases the probability of
curing more disease cases, while the price gap between combo and single tests are not so
huge.
How huge is “huge” and is double or triple “huge” enough? This is another complicated
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problem. The selection of testing assays depends not only on the prices of all assays but
also the parameters of assays like sensitivity and specificity. The relations between those
available assays are competing to each other. That is once we choose one test assay we can
never choose others. Here we have to introduce the “comparative advantage” to describe the
situation. A essay is chosen at a comparative low price and a comparative high performance
under certain budget. However, in the reasonable budget range (defined in section 4), this
assay is not always be chosen anytime. Calculation based on table in section 3 are attached
at appendix. We found Pace 2C Combo will never be selected in all time for it is expensive
and poor performance comparatively.
Table 6.1: Screening test assays
CT Baseline GC Baseline Cost
Test Sensitivity
Pace 2 CT 0.716 N/A 10.54
BDProbeTec CT 0.928 N/A 10.54
Culture 0.848 8.8
COBAS AMPLICOR CT/GC 0.84 0.924 19.92
Pace 2C Combo 0.716 0.781 4.28
BDProbeTec CT/GC 0.928 0.966 19.92
APTIMA CT/GC 0.942 0.992 25.27
Test Specificity
Pace 2 CT 0.995 N/A 10.54
BDProbeTec CT 0.981 N/A 10.54
Culture 1.000 8.8
COBAS AMPLICOR CT/GC 0.987 0.995 19.92
Pace 2C Combo 0.995 0.991 4.28
BDProbeTec CT/GC 0.981 0.994 19.92
APTIMA CT/GC 0.995 0.995 25.27
If we keep other parameters unchanged and decrease the price of Pace 2C Combe from
$14.28 to $4.28 as shown in the table 6.1, Then we see that this assay was selected in the
following graph. Furthermore, we expect that Pace 2C Combo will be selected while the
budget fall into the lower level of reasonable budget range for it is relatively cheap. On
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the upper level of the range, our model won’t select the test assay for its poor performance
comparatively. Generally speaking, one has the cheapest test assay which is combo and is
half price of the second cheapest test assays. Then one may always see that the cheapest
assay will be selected in the reasonable budget range.
Figure 6.3: The probability of selection on Pace 2C Combo increases to 34% due to price
decreased by $10.
6.3 Independence v.s. Dependence
All of above calculations are based on the assumption that 45% of GC patients are CT in-
fected. This is assumption that there exists a dependency between the two diseases. We also
calculate the optimal strategy under the assumption that the two diseases are independent
to each other. With the independent assumption, GC patients and patients who are not GC
infected have the same probability to get CT disease. The probability is Pt. Mathematically
speaking, we have Pt|g = Pt|g = Pt under independency. We find that the optimal strategy
curve calculated under independent assumption is below the curve under the assumption
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of dependence in Figure 6.4. At at budget of $50,000, we could have a cured case number
of 110 with the optimal strategy under independent assumption. However, with the same
budget, we could have 174 cured cases under dependent assumption. This is because with
certain budget we are likely to cure more people under the dependent assumption comparing
to independent assumption. Solid line in Figure 6.4 is the total cured disease cases under
dependence. Dotted line is the total cured disease cases under independence.
solid line: total cured disease cases under dependence.
dotted line: total cured disease cases under independence.
Figure 6.4: Independent curve is below dependent curve.
In Figure 6.5, we notice that under the independent assumption our model gives a
favorite of 60% to treat CT alone and suggests to cured CT and GC together with a partition
of 40%. However, under dependent assumption, our model gives more favorates to treat CT
and GC togehter with a 57% partition.
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(a) Treatment selection under independent
assumption
(b) Treatment selection under dependent as-
sumption
Figure 6.5: Our model gives favorite to single treatment under independent assumption.
6.4 Presumptive Treatment v.s. Non-presumptive Treatment
Presumptive treatment is to treat both of CT and GC on those CT test positive patients.
Non-presumptive treatment is the procedure to test CT first and and GC secondly with
corresponding single test assays, and finally to treat all of identified diseases. Presumptive
treatment is not as accurate as non-presumptive treatment and too much of it would lead
to antimicrobial resistance. If the two disease are dependent on each other, presumptive
treatment will be effective for it can help to identify the second disease at low costs by
testing smaller group with a high prevalence rate. With the data provided by CDC, the
cured disease case between presumptive and non-presumptive does not have much difference
because the procedure always require to test CT as the first step and then treat GC as an
additional payoff. However, the costs of non-presumptive treatment will be higher than that
of presumptive for it demands additional second test procedure on GC which costs extra
money.
CHAPTER 7
CONCLUSION AND FUTURE WORK
With our proposed two-step algorithm, the population groups, test assays and treatment
regimens could be easily added or deleted to the models. We could also get the more
accurate solution compare to Excel Solver’s algorithm for nonlinear model.
In our current model, our object is to maximize the number of cured disease cases
and the side effect of the tests and treatments are not concerned. For those mis-tested
and mistreated cases, we could add some punishments while calculating the total number
of cured cases. In another word, if there are too many mistested or mistreated cases with
certain assays, then the bad effects of the assays should be considered while selecting the
optimal strategy.
We have restricted our work on one clinic. Government funding agencies, such as CDC,
may need to optimize their funds for several clinics. Different clinics may use different
screening and treatment assays with more complicated constrains. The optimization problem
for the funding agencies is much more involved. We should set a goal in the future to tackle
this generalization problem.
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APPENDIX
The Parameters and the Mathematical Model in Details
Basic Parameters: The whole population is divided into 12 groups. The number of patients
and the prevalence of CT and GC in each group have been listed in Table 1.
For each group i, let Pt(i) and Pg(i) denote the prevalence rates of the group i with CT
and GC, respectively.
Table 7.1: Population distribution based 10,000 women
White Black Hispanics Others
<20 years 2010 480 360 150
20-24 years 2680 640 480 200
>24 years 2010 480 360 150
CT prevalence
<20 years 3.8% 15.6% 9.2% 10.7%
20-24 years 2.5% 14.4% 6.3% 7.5%
>24 years 1.2% 11.8% 2.5% 3.3%
GC prevalence
<20 years 0.1% 1.9% 0.1% 0.2%
20-24 years 0.2% 2.2% 0.1% 0.2%
>24 years 0.2% 1.8% 0.1% 0.2%
Let Pg|t(i) be the conditional probability of a CT patient in group i having GC disease
and Pt|g(i) be the conditional probability of a GC patient in group i having CT. From Bayes’
law, we obtain
Pt|g(i) =
Pt(i) · Pg|t(i)
Pg(i)
. (7.1)
Therefore, if Pg|t(i) is given, Pt|g(i) can be calculated by the above equation.
In order to calculate the cost, we also need the conditional probability of GC infection
of a patient without CT infection. Pg|t(i) can be presented as the following:
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Pg|t(i) =
Pg(i)− Pt(i) · Pg|t(i)
1− Pt(i) (7.2)
Because Pg(i) = Pt(i) · Pg|t + (1− Pt(i)) · Pg|t(i).
Similarly, we need Pt|g(i) in the cost estimates. Pt|g(i) can be presented as the following:
Pt|g(i) =
Pt(i)− Pg(i) · Pt|g(i)
1− Pg(i) (7.3)
There are seven available screening assays. For each assay j (1 ≤ j ≤ 7), let Snt(j)
and Spt(j) denote the sensitivity and specificity for CT; let Sng(j) and Spg(j) denote the
sensitivity and specificity for GC; let Bc(j) and Ac(j) be the unit base cost and additional
cost. The details are provided in the Table 2.
Table 7.2: Screening test assays
CT Baseline GC Baseline
Test Sensitivity
Pace 2 CT 0.716 N/A
BDProbeTec CT 0.928 N/A
Culture 0.848
COBAS AMPLICOR CT/GC 0.84 0.924
Pace 2C Combo 0.716 0.781
BDProbeTec CT/GC 0.928 0.966
APTIMA CT/GC 0.942 0.992
Test Specificity
Pace 2 CT 0.995 N/A
BDProbeTec CT 0.981 N/A
Culture 1.000
COBAS AMPLICOR CT/GC 0.987 0.995
Pace 2C Combo 0.995 0.991
BDProbeTec CT/GC 0.981 0.994
APTIMA CT/GC 0.995 0.995
There are two medications for treating CT and two medications for treating GC. Let
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z(k,l) be the binary indicator such that z(k,l) = 1 if treatment method (using assay k for CT
and/or assay l for GC) is selected and 0 otherwise.
For each CT treatment assay k (1 ≤ k ≤ 2), let Et(k) denotes the effectiveness of the
kth assay. Similarly, let Eg(l) denote the effectiveness of the lth (1 ≤ l ≤ 2) assay for GC
treatment. We also denote costs of drugs corresponding to CT and GC, Dct(k) and Dcg(l).
The details are provided in Table 3.
A return probability for treatment among patients who had positive test results, Pr was
0.86.
Number of Cured Cases: Let Curijkl denote the ratio of cured disease cases over pop-
ulation of the ith group using jth screening test and (k, l) method of treatment. So the
corresponding number of cases cured is Pop(i) ·Curijkl. There are five different scenarios to
calculate the cured disease cases and costs:
(1). Single screening test and single treatment targeting on CT. A CT test is given and
then a CT treatment is provided for those who tested positively, so the following holds
Curijkl = Pt(i) · Snt(j) · Et(k) · Pr. (7.4)
(2). Sequence screening tests that tested CT first.
A CT screening test is given to ith population group, then a GC test is given to those who
tested positively on CT. A CT medication is given for those who tested positively on CT
and a GC medication is given for those in addition tested positively on GC. Extra GC cured
cases shall be added to (7.4) in this scenario :
• Pt(i) · Snt(j) gives the ratio over the population of group i tested positively by using
the jth CT screening test;
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• Pt(i) · Snt(j) · Pg|t(i) · Sng(j) ·Eg(l) · Pr gives the ratio of the cured number of the GC
patients infected by both of CT and GC and tested both positively.
• (1− Pt(i)) · (1− Spt(j)) is the ratio of those not infected by CT but tested positively.
So (1 − Pt(i)) · (1 − Spt(j)) · Pg|t(i) · Sng(j) gives the percentage of patients who are
in a ”stroke of good luck” case. In this case, patients only have GC disease and were
accidently confided having CT with the jth test firstly and were caught with the second
GC test finally, which in turn shows that (1−Pt(i))·(1−Spt(j))·Pg|t(i)·Sng(j)·Eg(l)·Pr
is the percentage of the cured amount of GC patients in the case of the ”stroke of good
luck”.
Curijkl = Curijkl in (7.4) + Pt(i) · Snt(j) · Pg|t(i) · Sng(j) · Eg(l) · Pr
+(1− Pt(i)) · (1− Spt(j)) · Pg|t(i) · Sng(j) · Eg(l) · Pr (7.5)
(3). Single screening and treating for GC only.
A GC test is given and then a GC treatment is given to those who tested positively, so the
following holds.
Curijkl = Pg(i) · Sng(j) · Eg(l) · Pr (7.6)
(4). Sequence screening tests that tested GC first.
A GC screening test is given to ith population group, then a CT test is given to those who
tested positively on GC. A GC medication is given for those who test positively on GC and
a CT medication is given for those in addition tested positively on CT . Similar to (7.5), the
following holds.
Curijkl = Curijkl in (7.6) + Pg(i) · Sng(j) · Pt|g(i) · Snt(j) · Et(k) · Pr
+(1− Pg(i)) · (1− Spg(j)) ·Qt|g(i) · Snt(j) · Et(k) · Pr (7.7)
31
Note: Since GC prevalence is much smaller than CT prevalence, we expect that the prob-
ability of case (4) is much smaller than that case (2) in reality.
(5). Combo screening test for both CT and GC.
A combo test for both CT and GC is given and then a CT and a GC medicine treatment is
given to those tested positively on CT and GC, respectively. The following holds.
Curijkl = Curijkl in (7.4) + Curijkl in (7.6) (7.8)
Unit Costs: Let Costijkl denote the ratio of the cost over the population of the ith group
using jth test and get cured with kth and/or lth treatment assay(s). The corresponding
cost is Pop(i) ·Costijkl. There are also five different scenarios for calculating Costijkl, corre-
sponding to the Curijkl one to one. Since screening tests gives false positives, the calculation
of costijkl is more complicated.
(1). Single screening test and single treatment targeting on CT.
In this scenario, the group i was tested for CT screening test and then CT treatments were
given to those tested positively.
• Bct(j) + V c is the unit cost using the jth CT screening test and a unit visit costs at
the screening procedure.
• At the treatment procedure, Pt(i) · Snt(j) + (1− Pt(i)) · (1− Spt(j)) gives probability
of a person having a positive test result, where Pt(i) · Snt(j) is the probability of a
person having CT infection and tested positively and (1 − Pt(i)) · (1 − Spt(j)) is the
probability of a person not having CT infection but having a (false) positive result.
Although we do not consider the later case in estimating the number of cured cases,
we include it in costs.
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• Dct(k) + Tc, a charge on drug j and the treatment cost, gives the cost of medicine
treatment. So,
Costijkl = Bct(j) + V c + {Pt(i) · Snt(j)
+(1− Pt(i)) · (1− Spt(j))} · (Dct(k) + Tc) · Pr (7.9)
(2). Sequence screening tests that tested CT first.
With the strategy from this scenario, extra costs are added to (7.9) while curing GC patients.
However, no more visiting costs are charged.
• {Pt(i) · Snt(j) + (1−Pt(i)) · (1− Spt(j))} ·Bcg(j) represents the ratio over population
of GC testing costs for the patients tested positively on CT.
• {Pt(i) · Snt(j) · Pg|t(i) + (1 − Pt(i)) · (1 − Spt(j)) · Pg|t(i)} represents the ratio over
population of those tested positively on CT and then positively on GC. .
• {Pt(i) · Snt(j) ·Pg|t(i) + (1−Pt(i)) · (1− Spt(j)) ·Pg|t(i)} · Sng(j) · (Dcg(l) + Tc) ·Pr is
the ratio over the population of treatment costs for curing these patient with a positive
GC test.
• Summing the above counts, we have
Costijkl = Costijkl in (7.9) + {Pt(i) · Snt(j) + (1− Pt(i)) · (1− Spt(j))}
·Bcg(j) + {Pt(i) · Snt(j) · Pg|t(i) + (1− Pt(i)) · (1− Spt(j))
·Pg|t(i)} · Sng(j) · (Dcg(l) + Tc) · Pr (7.10)
(3). Single screening and treating for GC only.
A GC screening test is given first and then a GC treatment is given to those tested positively.
Similar to (7.9), we have
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Costijkl = Bcg(j) + V c + {Pg(i) · Sng(j)
+(1− Pg(i)) · (1− Spg(j))} · (Dcg(l) + Tc) · Pr (7.11)
(4). Sequence screening tests that tested for GC first.
Similar to (7.10), the following holds.
Costijkl = Costijkl in (7.11) + {Pg(i) · Sng(j) + (1− Pg(i)) · (1− Spg(j))}
·Bct(j) + {Pg(i) · Sng(j) · Pt|g(i) + (1− Pg(i)) · (1− Spg(j))
·Pt|g(i)} · Snt(j) · (Dct(k) + Tc) · Pr (7.12)
(5). Combo screening test for both CT and GC.
Costijkl in (7.4) + Costijkl in (7.11) will give the basic counting except the visit costs for
screening test is counted twice and the treatment cost for those tested positively on both
CT and GC is counted twice. Subtracting them, we obtain the following.
Costijkl = Costijkl in (7.9) + Costijkl in (7.11)
−Vc − Pt(i) · Pg|t(i) · Tc · Pr (7.13)
Note: For a combo assay, it has an additional cost which is calculated slightly different
from (7.13). Thus, we added the extra costs to the previous formulae and it is
Costijkl = Costijkl in (7.13) + {Pt(i) · Snt(j)
+Pg(i) · Sng(j)− Pt(i) · Pg|t(i)} · Ac(j) (7.14)
Target function and constraints: The target function is to maximize the cured cases
with available screening assays and treatment medications for several patient groups.
Max
∑
i,j,k,l
Curijkl · xiyjz(k,l) :=
12∑
i=1
7∑
j=1
2∑
k=0
2∑
l=0
Curijkl · xiyjz(k,l). (7.15)
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Subject to
∑
i,j,k,l
Popi · Costijkl · xiyjz(k,l) ≤ b and (7.16)
which means the screening and treatment costs for identified groups should be smaller than
the annual funding b available to a clinic.
furthermore,
7∑
j=1
yj = 1 and (7.17)∑
k,l
z(k,l) = 1. (7.18)
which implies that same screening assays and treatments are applied to all patients. At the
same time z(0,0) = 0.
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Table 7.3: All costs1 and treatment assays
Baseline2 Range L Range H
Test Cost
Pace 2 CT 18.5 8.97 28.02
BDProbeTec CT 29.79 10.54 49.04
GC Culture 9.26 9.26
AMPLICOR PCR CT/GC 54.57 11.06 98.07
Pace 2C Combo3 35.16 14.28 56.03
BDProbeTec CT/GC 59 19.92 98.07
APTIMA CT/GC 61.67 25.27 98.07
Treatment Efficacy-CT
Doxycycline 0.92 0.9 0.99
Azithromycin 0.92 0.9 0.99
Treatment Efficacy-GC
Doxycycline 0.64 0.3 0.9
Azithromycin 0.976 0.957 0.989
Ceftriaxone 0.988 0.979 0.998
Cefpodoxime proxetil 0.959 0.936 1
Treatment Cost4
Doxycycline 8.12 0.57 8.12
Azithromycin 16.65 21.35 27.5
Ceftriaxone 25.74 15.67 31.86
Cefpodoxime proxetil 8.28 8.28 10.52
Test Visit Cost 14
Treatment Visit Cost 28.43
Probability of PID 0.20 0.10 0.40
Prob. of return for treatment 0.86 0.76 0.91
Sequelae Cost
PID 2772 1366 4099
1All costs in 2006 US dollars (adjusted with medical CPI where needed).
2Baseline of test costs are the averages of Range L and Range H.
3 For the Pace 2C, a positive test (indicating either CT or GC, but not which organism) is
followed by two separate supplemental.
4 To this should be added a cost of dispensing/administration (treatment visit cost).
For ceftriaxone, the baseline price includes the drug plus the CMS fee for intramuscular
injection.
